BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 11704341)

  • 1. Dosimetric verification of a dedicated 3D treatment planning system for episcleral plaque therapy.
    Knutsen S; Hafslund R; Monge OR; Valen H; Muren LP; Rekstad BL; Krohn J; Dahl O
    Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):1159-66. PubMed ID: 11704341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosimetry of (125)I and (103)Pd COMS eye plaques for intraocular tumors: report of Task Group 129 by the AAPM and ABS.
    Chiu-Tsao ST; Astrahan MA; Finger PT; Followill DS; Meigooni AS; Melhus CS; Mourtada F; Napolitano ME; Nath R; Rivard MJ; Rogers DW; Thomson RM
    Med Phys; 2012 Oct; 39(10):6161-84. PubMed ID: 23039655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A practical approach to estimating optic disc dose and macula dose without treatment planning in ocular brachytherapy using
    Lee YC; Lin SC; Kim Y
    Radiat Oncol; 2018 Nov; 13(1):221. PubMed ID: 30424782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monte Carlo simulation of COMS ophthalmic applicators loaded with Bebig I25.S16 seeds and comparison with planning system predictions.
    Miras H; Terrón JA; Lallena AM
    Phys Med; 2013 Nov; 29(6):670-6. PubMed ID: 22858007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced Collapsed cone Engine dose calculations in tissue media for COMS eye plaques loaded with I-125 seeds.
    Morrison H; Menon G; Larocque MP; van Veelen B; Niatsetski Y; Weis E; Sloboda RS
    Med Phys; 2018 Jul; 45(7):3349-3360. PubMed ID: 29729009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of material heterogeneity dosimetric effects using radiochromic film for COMS eye plaques loaded with (125)I seeds (model I25.S16).
    Acar H; Chiu-Tsao ST; Ozbay I; Kemikler G; Tuncer S
    Med Phys; 2013 Jan; 40(1):011708. PubMed ID: 23298078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of dose calculation methods for brachytherapy of intraocular tumors.
    Rivard MJ; Chiu-Tsao ST; Finger PT; Meigooni AS; Melhus CS; Mourtada F; Napolitano ME; Rogers DW; Thomson RM; Nath R
    Med Phys; 2011 Jan; 38(1):306-16. PubMed ID: 21361199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monte Carlo dosimetry for 125I and 103Pd eye plaque brachytherapy with various seed models.
    Thomson RM; Rogers DW
    Med Phys; 2010 Jan; 37(1):368-76. PubMed ID: 20175499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monte Carlo dosimetry for 103Pd, 125I, and 131Cs ocular brachytherapy with various plaque models using an eye phantom.
    Lesperance M; Martinov M; Thomson RM
    Med Phys; 2014 Mar; 41(3):031706. PubMed ID: 24593710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosimetric study of the 15 mm ROPES eye plaque.
    Granero D; Pérez-Calatayud J; Ballester F; Casal E; de Frutos JM
    Med Phys; 2004 Dec; 31(12):3330-6. PubMed ID: 15651616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and dosimetric considerations of a modified COMS plaque: the reusable "seed-guide" insert.
    Astrahan MA; Szechter A; Finger PT
    Med Phys; 2005 Aug; 32(8):2706-16. PubMed ID: 16193802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigating the dosimetric impact of seed location uncertainties in Collaborative Ocular Melanoma Study-based eye plaques.
    Johnson JE; Deufel CL; Furutani KM
    Brachytherapy; 2016; 15(5):661-8. PubMed ID: 27475484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Independent dosimetric assessment of the model EP917 episcleral brachytherapy plaque.
    Aryal P; Molloy JA; Rivard MJ
    Med Phys; 2014 Sep; 41(9):092102. PubMed ID: 25186402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monte Carlo dosimetry for 125I and 103Pd eye plaque brachytherapy.
    Thomson RM; Taylor RE; Rogers DW
    Med Phys; 2008 Dec; 35(12):5530-43. PubMed ID: 19175111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental validation of a new COMS-like 24 mm eye plaque for the treatment of large ocular melanoma tumors.
    McCauley Cutsinger S; Forsman R; Corner S; Deufel CL
    Brachytherapy; 2019; 18(6):890-897. PubMed ID: 31444131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of 16 mm OSU-Nag and COMS eye plaques.
    Zhang H; Davidorf F; Qi Y
    J Appl Clin Med Phys; 2012 May; 13(3):3632. PubMed ID: 22584165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A practical method of estimating medium-heterogeneity corrected dose without a Monte Carlo calculation in ocular brachytherapy using
    Lee YC; Nik Akhtar M; Kim Y; Jung JW
    Brachytherapy; 2024; 23(3):377-386. PubMed ID: 38336557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosimetry for 125I seed (model 6711) in eye plaques.
    Chiu-Tsao ST; Anderson LL; O'Brien K; Stabile L; Liu JC
    Med Phys; 1993; 20(2 Pt 1):383-9. PubMed ID: 8497229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incorporating patient-specific CT-based ophthalmic anatomy in modeling iodine-125 eye plaque brachytherapy dose distributions.
    Tien CJ; Astrahan MA; Kim JM; Materin M; Chen Z; Nath R; Liu W
    Brachytherapy; 2017; 16(5):1057-1064. PubMed ID: 28778599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosimetric comparison of circular Eye Physics and Collaborative Ocular Melanoma Study plaques to treat uveal melanoma.
    Dean MK; Studenski MT; Paez-Escamilla MA; Walter SD; Kwon D; Markoe AM; Harbour JW; Samuels SE
    Brachytherapy; 2019; 18(3):404-410. PubMed ID: 30797699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.